BAYZF - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
89.69
+0.00 (+0.00%)
At close: 10:18AM EDT
Stock chart is not supported by your current browser
Previous Close89.69
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume11,092
Market Cap82.523B
Beta1.14
PE Ratio (TTM)10.06
EPS (TTM)8.91
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-04-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • Bayer cuts forecasts on Monsanto delay as lawsuits pile up
    Reuters Videos20 days ago

    Bayer cuts forecasts on Monsanto delay as lawsuits pile up

    Bayer has cut its earnings forecast due to delays to its $63 billion takeover of Monsanto, and said sales of its consumer care products fell, hitting its shares, already reeling from a legal battle over the weed killer Roundup. Thuy Ong reports

  • Reuters4 days ago

    Bayer hemophilia treatment wins thumbs-up from EU panel

    Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily. While final approvals are up to the European Commission, it generally follows recommendations from the Committee for Medicinal Products for Human Use (CHMP) and endorses them within a couple of months. The U.S. Food and Drug Administration last month approved https://in.reuters.com/article/us-bayer-fda/bayers-hemophilia-a-treatment-gets-u-s-fda-approval-idINKCN1LF17B the injection for previously treated patients and adolescents aged 12 years or older, judging it helped replace the reduced or missing protein, factor VIII, required to form blood clots.

  • The Wall Street Journal6 days ago

    [$$] Bayer Steps Up Legal Fight Over Weed Killer Blamed for Cancer

    Bayer AG is stepping up the legal defense of its flagship weedkiller, after a recent verdict in a case alleging the chemical causes cancer sent shares down sharply and raised the prospect of costly plaintiff payouts. The German company on Tuesday said it wants a California state court judge to overturn the jury’s verdict, order a new trial or reduce damages, according to a court filing. The $289 million award granted in August came in one of the first of thousands of cases filed by gardeners, farmers and others claiming Bayer’s Roundup herbicide gave them cancer.

  • Reuters6 days ago

    Colombia's coca cultivation hits record in 2017 - U.N.

    Colombia's acreage of coca, the raw material for cocaine, expanded 17 percent to hit a new record last year, the United Nations said on Wednesday, as the government mulls whether to restart aerial fumigation with the herbicide glyphosate. The total area of the Andean nation under coca cultivation increased to 171,000 hectares (422,550 acres) by the end of 2017, according to the United Nations Office on Drugs and Crime, due to increased productivity and growers eager to expand in the hope of getting more aid to switch to legal crops. The figure is the largest since the U.N. began keeping records, it said, adding that potential cocaine production was 1,379 metric tons last year.

  • Monsanto asks judge to throw out $289M award in cancer suit
    Associated Press6 days ago

    Monsanto asks judge to throw out $289M award in cancer suit

    SAN FRANCISCO (AP) — Agribusiness company Monsanto has asked a San Francisco judge to throw out a jury's $289 million award to a former school groundskeeper who said the company's Roundup weed killer left him dying of cancer.

  • Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict
    Reuters6 days ago

    Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict

    The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson. Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate. Monsanto asked Superior Court Judge Suzanne Bolanos, who oversaw the trial, to set aside the verdict or, in the alternative, reduce the award or grant a new trial.

  • Reuters6 days ago

    Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict

    Bayer AG unit Monsanto on Tuesday asked a California judge to throw out a $289 million jury verdict awarded to a man who alleged the company's glyphosate-based weed-killers, including Roundup, gave him cancer. The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson. Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate.

  • Reuters7 days ago

    Bayer says agriculture trade flows may change amid tariffs dispute

    Bayer (BAYGn.DE) said on Tuesday it would be difficult to predict 2019 earnings at its agriculture business, which now includes Monsanto, because a U.S.-Chinese trade dispute could reroute global trade flows in farming commodities. The head of Bayer's crop science division told Reuters his company could even benefit if U.S. farmers switched to grow more corn to avoid barriers to the soy trade imposed by China in response to U.S. tariffs on Chinese products. "The big unknown next year will be how U.S. farmers react to the Chinese-U.S. trade war," Liam Condon said on the sidelines of a news conference at the division's headquarters in Monheim, Germany.

  • Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
    Zacks7 days ago

    Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

    Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

  • The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

    The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

  • Reuters8 days ago

    Exclusive: Bayer puts stake in chemical park operator up for sale-sources

    Bayer is inviting financial investors to bid for its 60 percent stake in chemical park operator Currenta after initially failing to agree a sale to its former chemicals subsidiary Covestro, three people familiar with the matter told Reuters. Bayer, which is focusing on healthcare and crop protection after the takeover of U.S. seed maker Monsanto, has mandated Morgan Stanley to help with the transaction. Currenta, which operates infrastructure facilities at German chemical complexes in Leverkusen, Dormagen and Krefeld-Uerdingen, could be valued at upwards of 1 billion euros ($1.2 billion) and possibly more than 2 billion, according to one of the sources.

  • Bayer May Face Next Roundup Cancer Trial Sooner Than Planned
    Bloomberg11 days ago

    Bayer May Face Next Roundup Cancer Trial Sooner Than Planned

    The husband and wife in their 70s are invoking the same California law -- which gives scheduling preference to people who are terminally ill -- that allowed a school groundskeeper diagnosed with just months to live to stage the first Roundup trial this summer, resulting in a $289 million verdict. Bayer Chief Executive Officer Werner Baumann sought to assure assure investors in a Sept. 5 conference call that the merger with Monsanto will beef up the companies’ legal firepower to defeat the sprawling litigation.

  • Bayer's pharma unit head Weinand quits to join Sanofi
    Reuters12 days ago

    Bayer's pharma unit head Weinand quits to join Sanofi

    Bayer (BAYGn.DE), which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi (SASY.PA) to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.

  • The Wall Street Journal12 days ago

    [$$] Sanofi Poaches Bayer Manager to Lead Unit

    Sanofi hired the head of Bayer’s pharmaceuticals division to lead its Primary Care unit, one of two new divisions that the French company is creating.

  • Sanofi and Bayer Are Swapping Executives
    Bloomberg12 days ago

    Sanofi and Bayer Are Swapping Executives

    Sanofi and Bayer AG, two European drugmakers with blockbuster medicines facing headwinds, are swapping top executives. Sanofi is bringing in Bayer’s Dieter Weinand as executive vice president in charge of a new unit that combines its diabetes and cardiovascular operations with a broader group of established products, the Paris-based company said in a statement Thursday. At the same time, Stefan Oelrich, head of diabetes at Sanofi, will replace Weinand as the head of Bayer’s pharmaceuticals division in November.

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of BAYN.DE earnings conference call or presentation 5-Sep-18 12:00pm GMT

    Q2 2018 Bayer AG Earnings Call

  • The Wall Street Journal20 days ago

    [$$] Bayer Says More Americans Are Alleging Monsanto Weedkillers Cause Cancer

    BERLIN—Bayer AG said the number of American plaintiffs alleging its recently acquired weedkillers cause cancer has risen sharply, adding to concerns about potentially lengthy and costly litigation stemming from its acquisition of Monsanto. The German chemicals company on Wednesday also lowered its full-year earnings outlook because of delays in closing its $63 billion purchase of Monsanto, which included a portfolio of herbicides that contain glyphosate, notably flagship product Roundup. Bayer said it faced some 8,700 plaintiffs across the U.S. as of late August—mainly cancer patients who claim to have fallen ill after being exposed to the glyphosate-containing Monsanto herbicides.

  • Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout
    Zacks20 days ago

    Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout

    Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.

  • Reuters20 days ago

    Bayer cuts forecasts on Monsanto delay as lawsuits pile up

    Bayer cut its earnings forecast on Wednesday due to delays to its $63 billion takeover of Monsanto, and said sales of its consumer care products fell, hitting its shares, already reeling from a legal battle over the weed killer Roundup. The weaker earnings forecast adds to a number of challenges facing the German drugmaker as it braces for years of legal wrangling over the alleged cancer risks of glyphosate-based weedkillers. Bayer said the number of plaintiffs seeking damages over Monsanto's Roundup and Ranger Pro herbicides had risen to 8,700 from 8,000 from last month, and said that it expected more to sue.

  • Bayer cuts forecasts on Monsanto delay as lawsuits pile up
    Reuters20 days ago

    Bayer cuts forecasts on Monsanto delay as lawsuits pile up

    Bayer cut its earnings forecast on Wednesday due to delays to its $63 billion takeover of Monsanto, and said sales of its consumer care products fell, hitting its shares, already reeling from a legal battle over the weed killer Roundup. The weaker earnings forecast adds to a number of challenges facing the German drugmaker as it braces for years of legal wrangling over the alleged cancer risks of glyphosate-based weedkillers. Bayer said the number of plaintiffs seeking damages over Monsanto's Roundup and Ranger Pro herbicides had risen to 8,700 from 8,000 from last month, and said that it expected more to sue.

  • Monsanto Still Sows the Seeds of Doubt
    Bloomberg20 days ago

    Monsanto Still Sows the Seeds of Doubt

    Investors weren’t willing to give Werner Baumann the benefit of the doubt when Bayer AG’s CEO moved to shift the drugmaker’s business to crop science by buying U.S. seeds giant Monsanto Co. Reaction to the latest unwelcome news about the deal shows the credibility deficit persists. Bayer warned on Wednesday that this year’s earnings per share would fall by a high single-digit percentage because of the timing of the Monsanto purchase. As the deal completed on June 7, a little later than hoped, the contribution to Bayer’s second-quarter numbers was small.

  • Bayer CEO on Lower Earnings, Monsanto Purchase, Roundup
    Bloomberg20 days ago

    Bayer CEO on Lower Earnings, Monsanto Purchase, Roundup

    Werner Baumann, chief executive officer at Bayer, discusses the company's lower earnings forecast, the Monsanto purchase and the company's Roundup lawsuit. He speaks on "Bloomberg Markets: European ...

  • The Wall Street Journal20 days ago

    [$$] Bayer Cuts Guidance After Profit Drop

    AG (BAYN.XE) on Wednesday adjusted its 2018 guidance to reflect the acquisition of Monsanto as it reported a sharp decline in second-quarter earnings. AG (1COV.XE), which now reports as a separate company, Bayer said. The German conglomerate issued new financial guidance to reflect the Monsanto acquisition and the divestment of several businesses, including its vegetable-seeds unit.

  • Bayer Warns on Profit Outlook After $63 Billion Monsanto Deal
    Bloomberg20 days ago

    Bayer Warns on Profit Outlook After $63 Billion Monsanto Deal

    Bayer AG’s $63 billion Monsanto purchase has suffered regulatory delays, mounting legal claims and now will yield lower earnings for the year than earlier forecast. “The Monsanto business is very healthy,” Chief Executive Officer Werner Baumann said Wednesday in an interview with Bloomberg TV. While acquiring Monsanto made Bayer the biggest seed and agricultural-chemicals maker in the world, the purchase has been dogged by a series of challenges from regulators and legal pitfalls.

  • Bloomberg20 days ago

    Bayer's Delays in Monsanto Purchase Hurt Earnings Forecast

    Delays to Bayer AG’s $63 billion purchase of agricultural giant Monsanto pushed the acquisition past the new unit’s busiest season, and the company said earnings for the year will be lower than forecast. Core earnings per share will probably reach about 5.70 euros to 5.90 euros, the Leverkusen, Germany-based company said Wednesday in a statement. The Monsanto acquisition, which closed in June, has made Bayer the biggest seed and agricultural chemicals maker in the world, yet it’s been overshadowed by the legal battle over the weed killer Roundup, one of Monsanto’s most important products.